BEIJING CHONGXIN TECHNOLOGY CO., LTD. – Trademark Portfolio

Entity Type: 22

BEIJING CHONGXIN TECHNOLOGY CO., LTD. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include JRAIAAOD. The owner is based in BEIJING.

ROOM 2049, 2ND FLOOR, BLOCK C, YA'AN COMMERCIAL BUILDING, NORTH SIDE OF DINGSI ROAD, BEIQIJIA TOWN, CHANGPING DISTRICT

BEIJING 100000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

JRAIAAOD
JRAIAAOD
Registered 2025

Trademark Classifications

BEIJING CHONGXIN TECHNOLOGY CO., LTD.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does BEIJING CHONGXIN TECHNOLOGY CO., LTD. have?

BEIJING CHONGXIN TECHNOLOGY CO., LTD. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does BEIJING CHONGXIN TECHNOLOGY CO., LTD. file in?

BEIJING CHONGXIN TECHNOLOGY CO., LTD. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are BEIJING CHONGXIN TECHNOLOGY CO., LTD.'s most well-known trademarks?

BEIJING CHONGXIN TECHNOLOGY CO., LTD.'s registered trademark portfolio includes well-known marks such as JRAIAAOD. These are among 1 currently registered trademark in the portfolio.

What is BEIJING CHONGXIN TECHNOLOGY CO., LTD.'s trademark registration success rate?

BEIJING CHONGXIN TECHNOLOGY CO., LTD. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.